Key Takeaways
- Visual acuity remained stable one year after switching to aflibercept 8 mg.
- Retinal anatomy improved, with reduced central subfield thickness and more eyes without retinal fluid.
- Treatment intervals lengthened, with the average interval increasing from 7.1 to 9.4 weeks.
Switching to intravitreal aflibercept 8 mg in patients with previously treated neovascular age-related macular degeneration (nAMD) was associated with anatomical improvements and longer treatment intervals while visual acuity remained stable over 12 months in a real-world setting.
The longitudinal observational study included 283 eyes from 245 patients who had previously received aflibercept 2 mg, faricimab, or ranibizumab. One-year efficacy outcomes were available for 246 eyes, while safety was assessed in all treated eyes.
After 12 months of treatment, mean visual acuity remained stable. Mean central subfield thickness decreased from 329.1 µm at baseline to 302.8 µm (P < 0.001). The proportion of eyes without retinal fluid increased from 29.9% at baseline to 47.5% at 1 year.
Treatment intervals also lengthened over the study period. The average interval increased by 32.3%, from 7.1 weeks to 9.4 weeks (P < 0.001). At the 1-year mark, 35.4% of eyes were maintained on treatment intervals between 8 and 11 weeks, and 20.2% achieved intervals of 12 weeks or longer.
In terms of safety, intraocular inflammation occurred in 3.9% of treated eyes.
Reference
Kitay AM, Tillmann A, Pfister I, et al. One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. Ophthalmol Ther. 2026;doi: 10.1007/s40123-026-01344-x. Epub ahead of print. PMID: 41779364.
Related Content
